Generated September 2026 · Clinical Deep Dive 0 Comments Ask five thoracic oncologists whether a patient needs a year of adjuvant immunotherapy after neoadjuvant chemo-immunotherapy, and you may get five different answers. No randomized trial has directly tested whether the adjuvant year adds benefit. Two years is another common checkpoint-inhibitor stopping point…
Read More
